Industry confident of Supreme Court victory

Data firms and pharmas are feeling confident after the Supreme Court arguments on Vermont's physician data ban.
“Based on the tenor of the questioning that I saw and the body language of certain justices, there appear to be five solid conservative votes,” said Christopher Mohr, an attorney with Meyer, Klipper & Mohr, which served as counsel on an amicus brief in support of the data firms.
Coalition for Healthcare Communication head John Kamp concurred, saying: “The tenor of the Justices so clearly signaled defeat for Vermont that we may see a decision before June.”
Conservative justices skewered Vermont's arguments on free speech grounds from the start.
“You want to lower your healthcare costs, not by direct regulation, but by restricting the flow of information to doctors…by censoring what they can hear to make sure they don't have full information, so that they will do what you want them to do when it comes to prescribing drugs,” said Chief Justice Roberts. The court's right-leaning swing vote, Justice Kennedy, followed up by asking: “In effect, aren't you doing this by regulating speech?”
The court's liberal wing was scarcely more sympathetic to Vermont, with Justice Sotomayor questioning why the law was needed if doctors could already opt out of having their data used commercially, and Justice Ginsburg wondering: “If [advantaging generics] is the purpose, why doesn't that run up against what this court has said that you can't lower the decibel level of one speaker so that another speaker…can be heard better?”
You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.